<DOC>
	<DOCNO>NCT00975897</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor select best treatment patient predict response treatment . PURPOSE : This randomized phase II/III trial study well tumor tissue test work select treatment patient metastatic locally advanced colorectal cancer .</brief_summary>
	<brief_title>Study Tumor Tissue Testing Selecting Treatment Patients With Metastatic Locally Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Feasibility Study - To determine proportion consent patient provide formalin-fixed paraffin-embedded block contain tumor . - To determine feasibility topoisomerase-1 ( topo-1 ) IHC K-ras , BRAF mutational status determination complete 10 work day initial consent . - To determine reproducibility result reference laboratory . - To determine real cost molecular test . - To determine patient ' ability comprehend study attitude wait period test . - To assess patient ' ability fully comprehend trial explain . Secondary - Feasibility Study - To identify EGFR-responsive subset within K-ras wildtype population . Primary - Definitive Study - Compare clinical outcome patient metastatic locally advanced colorectal cancer low topo-1-expressing tumor treat fluorouracil alone versus irinotecan hydrochloride , fluorouracil , leucovorin calcium ( IrMdG ) . - Compare progression-free survival patient high topo-1-expressing tumor treat oxaliplatin IrMdG versus IrMdG alone . - Compare response rate patient K-ras wildtype tumor treat cetuximab IrMdG versus IrMdG alone . - Compare response rate patient K-ras mutant tumor unlikely respond EGFR inhibition treat bevacizumab IrMdG versus IrMdG alone . OUTLINE : This multicenter , 2-part study . - Part I ( feasibility study ) : Once consent tissue block release obtain patient register , block request Pathology Department . This begin 10 working-day time line . Treatment commences result test know . The following evaluation perform period : - The frequency EGFR gene amplification FISH , PI3K gene mutation , PTEN loss IHC , estimation mRNA EGFR ligands ( amphiregulin epiregulin ) , protein assessment . - An evaluation impact use investigation marker main study . - Patients consent trial entry ( agreeable data collection ) patient refuse trial entry complete questionnaire assess patient ' ability fully comprehend trial explain . - Patients interviewed allocation treatment attitude wait period necessary tumor test . - Part II ( definitive study ) : Patients stratify accord availability lab test ( K-ras mutation [ yes vs ] , BRAF mutation [ yes vs ] , topoisomerase-1 [ topo-1 ] expression [ low vs high ] ) . Patients assign 1 4 treatment group base biomarker test result . - Group 1 ( low topo-1 K-ras BRAF wildtype ) : Patients randomize 1 3 treatment arm . - Arm I ( regimen A [ IrMdG ] ) : Patients receive irinotecan hydrochloride IV 30 minute , leucovorin calcium IV 2 hour , fluorouracil IV bolus follow infusion 46 hour day 1 . Treatment repeat every 2 week least 6 month absence disease progression unacceptable toxicity . - Arm II ( regimen B [ MdG ] ) : Patients receive leucovorin calcium IV 2 hour fluorouracil IV bolus follow infusion 46 hour day 1 . Treatment repeat every 2 week least 6 month absence disease progression unacceptable toxicity . - Arm III ( regimen D [ IrMdG cetuximab ] ) : Patients receive cetuximab IV 1-2 hour , irinotecan hydrochloride IV 30 minute , leucovorin calcium IV 2 hour , fluorouracil IV bolus follow infusion 46 hour day 1 . Treatment repeat every 2 week least 6 month absence disease progression unacceptable toxicity . - Group 2 ( low topo-1 either K-ras BRAF mutation ) : Patients randomize 1 3 treatment arm . - Arm I ( regimen A [ IrMdG ] ) : Patients receive irinotecan hydrochloride , leucovorin calcium , fluorouracil group 1 , arm I . - Arm II ( regimen B [ MdG ] ) : Patients receive leucovorin calcium fluorouracil group 1 , arm II . - Arm III ( regimen E [ IrMdG bevacizumab ] ) : Patients receive bevacizumab IV 30-90 minute , irinotecan hydrochloride IV 30 minute , leucovorin calcium IV 2 hour , fluorouracil IV bolus follow infusion 46 hour day 1 . Treatment repeat every 2 week least 6 month absence disease progression unacceptable toxicity . - Group 3 ( high topo-1 K-ras BRAF wildtype ) : Patients randomize 1 3 treatment arm . - Arm I ( regimen A [ IrMdG ] ) : Patients receive irinotecan hydrochloride , leucovorin calcium , fluorouracil group 1 , arm I . - Arm II ( regimen C [ IrOxMdG ] ) : Patients receive irinotecan hydrochloride IV 30 minute , leucovorin calcium IV 2 hour , oxaliplatin IV 2 hour , fluorouracil IV bolus follow infusion 46 hour day 1 . Treatment repeat every 2 week least 6 month absence disease progression unacceptable toxicity . - Arm III ( regimen D [ IrMdG cetuximab ] ) : Patients receive cetuximab , irinotecan hydrochloride , leucovorin calcium , fluorouracil IV group 1 , arm III . - Group 4 ( high topo-1 either K-ras BRAF mutation ) : Patients randomize 1 3 treatment arm . - Arm I ( regimen A [ IrMdG ] ) : Patients receive irinotecan hydrochloride , leucovorin calcium , fluorouracil group 1 , arm I . - Arm II ( regimen C [ IrOxMdG ] ) : Patients receive irinotecan hydrochloride , leucovorin calcium , oxaliplatin , fluorouracil group 3 , arm II . - Arm III ( regimen E [ IrMdG bevacizumab ] ) : Patients receive bevacizumab , irinotecan hydrochloride , leucovorin calcium , fluorouracil IV group 2 , arm III . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 240 patient accrue feasibility study approximately 3,000 patient accrue definitive study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenocarcinoma meeting 1 follow criterion : Prior recurrent primary adenocarcinoma colon rectum clinical radiological evidence locally advance metastatic disease Metastatic adenocarcinoma clinical and/or radiological evidence colorectal primary tumor Inoperable metastatic locoregional disease Patients suitable surgical resection metastatic disease response firstline adjuvant chemotherapy allow consider NewEPOC trial study Unidimensionally measurable disease ( accord RECIST criterion ) Must complete adjuvant chemotherapy fluorouracil +/ leucovorin calcium ( FU +/ LC ) , capecitabine , oxaliplatin combination past 6 month QUASAR 2 patient continue bevacizumab 6 month follow completion chemotherapy allow immediately completion bevacizumab Rectal chemotherapy FU +/ LC capecitabine allow complete ≥ 1 month ago Single tumor block available No brain metastasis PATIENT CHARACTERISTICS : WHO performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Alkaline phosphatase ≤ 5 time upper limit normal ( ULN ) Serum bilirubin ≤ 1.25 time ULN AST ALT ≤ 2.5 time ULN Creatinine clearance ≥ 30 mL/min OR GFR ≥ 30 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Considered fit undergo combination chemotherapy , none follow condition : Severe uncontrolled concurrent medical illness likely interfere protocol treatment , include follow : Poorly control angina Uncontrolled hypertension Myocardial infarction within past 3 month History severe peptic ulcer disease Any psychiatric neurological condition likely compromise patient 's ability give inform consent comply oral medication Nephrotic syndrome Known coagulopathy No prior current malignant disease , judgement treat investigator , likely interfere FOCUS 3 treatment assessment response No known hypersensitivity reaction component study treatment No personal family history suggestive dihydropyrimidine dehydrogenase ( DPD ) deficiency know DPD deficiency No history uncontrolled seizure , central nervous system disorder , psychiatric disability judge investigator clinically significant precluding inform consent Not able attend comply treatment followup schedule PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior surgery No prior systemic chemotherapy metastatic disease No ongoing therapy cyclosporinA No ongoing treatment contraindicate concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>